Royal Pharmaceutical Society president Ash Soni has responded to C+D readers concerned that recruiting an extra 1,500 pharmacists into GP surgeries will divert funding away from community pharmacy
But Mr Soni told readers there is only a "low risk" that this will happen, while at Avicenna's conference in Mauritius on Tuesday (May 31).
NHS England's plans to quadruple the existing practice pharmacist pilot – announced in April – will not take money away from the sector as long as pharmacists "deliver the things they are capable of doing and the services they are commissioned for", he said.
Rather than a funding concern, the extra 1,500 GP pharmacists could be a " great opportunity for collaboration", Mr Soni added.
Watch Mr Soni's full response in the video above.
C+D poll reveals GP funding concerns...
Mr Soni made the comments in response to a C+D poll that revealed that half of 107 respondents fear the practice pharmacist initiative could divert money away. A further 7% said it could impact the services offered by their pharmacy.
...but also possible advantages
However, almost a quarter (23%) of respondents said the plans will lead to increased collaboration between their pharmacies and GP surgeries. A further 8% said increasing recruitment in general practice will reduce competition for roles in community pharmacy.
Thirteen per cent said the plans will have no impact on their pharmacy.
Read more: Pharmacy organisations were underwhelmed by the extra practice pharmacists when they were announced in April
What impact will extra practice pharmacists have on your pharmacy?
We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information
The views and opinions discussed during this video news blog represent those of the speakers and not of Actavis UK Ltd Actavis
Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard
Adverse events can also be reported to Actavis on 01271 385257
* ‘Patient safety is Actavis’ primary concern and we encourage healthcare professionals and patients to report any adverse event which may occur in relation to an Actavis product. An adverse event includes reports of any side effect, product misuse, abuse or overdose, including inappropriate use by children or women who are pregnant or breast-feeding. It also includes reports of a product that was used for something other than the intended purpose or was ineffective, or was given with another medicine. Complaints relating to the product can also be reported.’